Health Trials

Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

1

Review clinical trials related to Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 1b, open-label, multi-center study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HS-20093 in patients with advanced gastric and gastroesophageal junction adenocarcinoma.

Participants needed: 40
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hansoh BioMedical R&D CompanyUpdated: Mar 10, 2026Locations: 1
Eligibility criteria

At least age of 18 years at screening, with no restrictions on gender. [+9]

Previous or current treatment with B7-H3 targeted therapy. [+32]

Read more